Ganaxolone for use in treatment of status epilepticus
This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
1. A method of treating status epilepticus (SE), comprising administering to a subject in need thereof an effective amount of ganaxolone to suppress SE, wherein the effective amount of ganaxolone is administered as an intravenous bolus plus continuous infusion to produce and maintain a ganaxolone plasma concentration of about 500 ng/ml to about 1000 ng/ml for about 8 hours to about 12 hours.
2. The method of claim 1 , wherein the intravenous bolus comprises about 5 mg to about 40 mg of ganaxolone.
3. The method of claim 2 , wherein the intravenous bolus comprises about 30 mg of ganaxolone.
4. The method of claim 1 , wherein the continuous intravenous infusion comprises infusion of about 20 mg of ganaxolone per hour to about 80 mg of ganaxolone per hour.
5. The method of claim 4 , wherein about 80 mg of ganaxolone per hour are infused into the subject at the initiation of the continuous intravenous infusion and for at least about 2 hours thereafter.
6. The method of claim 5 , wherein the amount of ganaxolone infused into the subject by the continuous intravenous infusion is decreased from about 80 mg per hour to about 40 mg per hour after about 2 hours.
7. The method of claim 6 , wherein the 40 mg per hour continuous intravenous infusion is administered for about 6 hours to about 10 hours.
8. The method of claim 7 , further comprising continuing to administer ganaxolone by the continuous intravenous infusion, wherein the amount of ganaxolone infused is decreased to about 20 mg per hour.
9. The method of claim 8 , wherein the 20 mg per hour continuous intravenous infusion is administered for about 12 hours to about 24 hours.
10. The method of claim 2 , wherein a continuous intravenous infusion of ganaxolone is initiated periprocedurally with the intravenous bolus and the continuous intravenous infusion comprises: a) an infusion of about 80 mg ganaxolone per hour for about 2 hours, then b) an infusion of about 40 mg ganaxolone per hour for about 6 hours to about 10 hours, then c) an infusion of about 20 mg ganaxolone per hour for about 12 hours to about 24 hours.
11. The method of claim 1 , wherein the intravenous bolus produces a ganaxolone plasma concentration in the subject of about 500 ng/ml to about 1000 ng/ml.
12. The method of claim 10 , wherein the intravenous bolus is administered to the subject for about 1 minute to about 5 minutes.
13. The method of claim 10 , further comprising a taper period of about 12 hours.
14. The method of claim 1 , wherein the subject has refractory status epilepticus.
15. The method of claim 1 , wherein the amount of ganaxolone infused into the subject by the continuous infusion is decreased at least once while the ganaxolone plasma concentration of about 500 ng/ml to about 1000 ng/ml is maintained.
16. The method of claim 1 , wherein the total daily dose of ganaxolone administered is from about 500 mg to about 900 mg.
17. The method of claim 15 , further comprising continuing the intravenous infusion and reducing the amount of ganaxolone that is administered.
18. The method of claim 10 , wherein the subject has refractory status epilepticus.
19. The method of claim 17 , wherein the subject has refractory status epilepticus.
20. The method of claim 3 , wherein a continuous intravenous infusion of ganaxolone is initiated periprocedurally with the intravenous bolus and the continuous intravenous infusion comprises: a) an infusion of about 80 mg ganaxolone per hour for about 2 hours, then b) an infusion of about 40 mg ganaxolone per hour for about 6 hours to about 10 hours, then c) an infusion of about 20 mg ganaxolone per hour for about 12 hours to about 24 hours.
21. The method of claim 20 , wherein the subject has refractory status epilepticus.